STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[6-K] ASTRAZENECA PLC Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary

AstraZeneca PLC has published a Form 6-K reporting a TR-1 notification of major holdings. The Capital Group Companies, Inc. has crossed the 5% disclosure threshold in AstraZeneca’s voting rights. The group now holds a total of 77,811,893 voting rights, representing 5.017815% of AstraZeneca’s voting rights.

These voting rights are held indirectly through shares in two lines: common stock with ISIN GB0009895292 accounting for 4.239936% of voting rights, and depository receipts with ISIN US0463531089 accounting for 0.777879%. The position was previously 4.997854%, so this notice reflects a small increase above the 5% reporting threshold.

Positive
  • None.
Negative
  • None.
FORM 6-K
 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
Report of Foreign Issuer
 
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
 
For the month of November 2025 
 
Commission File Number: 001-11960
 
AstraZeneca PLC
 
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F X Form 40-F __
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
 
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
 
Yes __ No X
 
If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________
 
 
 
AstraZeneca PLC
 
INDEX TO EXHIBITS
 
 
1.
Holding(s) in Company
 
 
 
TR-1: Standard form for notification of major holdings
 
1. Issuer Details
 
ISIN
GB0009895292
 
 
Issuer Name
ASTRAZENECA PLC
 
 
UK or Non-UK Issuer
UK
 
 
2. Reason for Notification
 
An acquisition or disposal of voting rights
 
 
3. Details of person subject to the notification obligation
 
Name
The Capital Group Companies, Inc.
 
 
City of registered office (if applicable)
Los Angeles
 
 
Country of registered office (if applicable)
USA
 
 
4. Details of the shareholder
 
Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above
 
 
 
City of registered office (if applicable)
 
 
 
Country of registered office (if applicable)
 
 
 
5. Date on which the threshold was crossed or reached
 
13-Nov-2025
 
 
6. Date on which Issuer notified
 
15-Nov-2025
 
 
7. Total positions of person(s) subject to the notification obligation
 
 
% of voting rights attached to shares (total of 8.A)
% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)
Total of both in % (8.A + 8.B)
Total number of voting rights held in issuer
Resulting situation on the date on which threshold was crossed or reached
 
5.017815
 
0.000000
 
5.017815
 
77811893
 
Position of previous notification (if applicable)
 
4.997854
 
0.000000
 
4.997854
 
 
 
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached
 
 
8A. Voting rights attached to shares
 
Class/Type of shares ISIN code(if possible)
 
Number of direct voting rights (DTR5.1)
 
Number of indirect voting rights (DTR5.2.1)
 
% of direct voting rights (DTR5.1)
 
% of indirect voting rights (DTR5.2.1)
 
GB0009895292 Common Stock
 
 
65749228
 
 
4.239936
 
US0463531089 Depository Receipt
 
 
12062665
 
 
0.777879
 
    Sub Total 8.A
77811893
 
5.017815%
 
 
8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))
 
Type of financial instrument
Expiration date
Exercise/conversion period
Number of voting rights that may be acquired if the instrument is exercised/converted
% of voting rights
 
 
 
 
 
 
Sub Total 8.B1
 
 
 
 
 
8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))
 
Type of financial instrument
 
Expiration date
 
Exercise/conversion period
 
Physical or cash settlement
 
Number of voting rights
 
% of voting rights
 
 
 
 
 
 
 
 
Sub Total 8.B2
 
 
 
 
 
9. Information in relation to the person subject to the notification obligation
 
2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)
 
 
Ultimate controlling person
Name of controlled undertaking
% of voting rights if it equals or is higher than the notifiable threshold
% of voting rights through financial instruments if it equals or is higher than the notifiable threshold
Total of both if it equals or is higher than the notifiable threshold
The Capital Group Companies, Inc.
 
Capital Research and Management Company
 
 
 
 
The Capital Group Companies, Inc.
 
Capital International, Inc.
 
 
 
 
The Capital Group Companies, Inc.
 
Capital Group Private Client Services, Inc.
 
 
 
 
The Capital Group Companies, Inc.
 
Capital International Sarl
 
 
 
 
The Capital Group Companies, Inc.
 
Capital International Limited
 
 
 
 
 
10. In case of proxy voting
 
Name of the proxy holder
 
 
 
 
The number and % of voting rights held
 
 
 
 
The date until which the voting rights will be held
 
 
 
 
11. Additional Information
 
The Capital Group Companies, Inc. ("CGC") is the parent company of Capital Research and Management Company ("CRMC") and Capital Bank & Trust Company ("CB&T"). CRMC is a U.S.-based investment management company that serves as investment manager to the American Funds family of mutual funds, other pooled investment vehicles, as well as individual and institutional clients. CRMC and its investment manager affiliates manage equity assets for various investment companies through three divisions, Capital Research Global Investors, Capital International Investors and Capital World Investors. CRMC is the parent company of Capital Group International, Inc. ("CGII"), which in turn is the parent company of six investment management companies ("CGII management companies"): Capital International, Inc., Capital International Limited, Capital International Sàrl, Capital International K.K., Capital Group Private Client Services Inc, and Capital Group Investment Management Private Limited. CGII management companies primarily serve as investment managers to institutional and high net worth clients. CB&T is a U.S.-based registered investment adviser and an affiliated federally chartered bank.Neither CGC nor any of its affiliates own shares of the Issuer for its own account. Rather, the shares reported on this Notification are owned by accounts under the discretionary investment management of one or more of the investment management companies described above.
 
12. Date of Completion
 
15-Nov-2025
 
 
13. Place Of Completion
 
Los Angeles
 
 
 
 
 
 
 
 
 

 
 

 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
AstraZeneca PLC
 
 
Date: 17 November 2025
 
 
By: /s/ Matthew Bowden
 
Name: Matthew Bowden
 
Title: Company Secretary

FAQ

What major shareholding was disclosed in AstraZeneca (AZN) on this Form 6-K?

The filing reports that The Capital Group Companies, Inc. has notified AstraZeneca that it now holds 77,811,893 voting rights, representing 5.017815% of AstraZeneca’s voting rights, crossing the 5% major shareholding threshold.

How many AstraZeneca voting rights does Capital Group now control?

Capital Group’s notified holding amounts to 77,811,893 voting rights in AstraZeneca PLC, corresponding to 5.017815% of the company’s total voting rights.

How is Capital Group’s AstraZeneca (AZN) stake split between common stock and depository receipts?

The position is held via two lines: AstraZeneca common stock with ISIN GB0009895292 representing 4.239936% of voting rights, and depository receipts with ISIN US0463531089 representing 0.777879% of voting rights.

Did Capital Group’s percentage holding in AstraZeneca recently change?

Yes. The notification shows the resulting situation at 5.017815% of voting rights, compared with a previous position of 4.997854%, indicating a modest increase that moved the holding above the 5% threshold.

Does Capital Group hold any AstraZeneca voting rights through financial instruments?

No financial instruments are reported. The tables for financial instruments (sections 8B1 and 8B2) show no voting rights or percentages, indicating the notified position is based on voting rights attached to shares only.

Who are the controlled undertakings linked to The Capital Group Companies, Inc. in this AstraZeneca holding?

The notification lists several controlled undertakings under The Capital Group Companies, Inc., including Capital Research and Management Company, Capital International, Inc., Capital Group Private Client Services, Inc., Capital International Sarl, and Capital International Limited.

Astrazeneca Plc

NASDAQ:AZN

AZN Rankings

AZN Latest News

AZN Latest SEC Filings

AZN Stock Data

277.19B
3.10B
0%
16.74%
0.25%
Drug Manufacturers - General
Healthcare
Link
United Kingdom
Cambridge